Table 1.
Demographic and clinical characteristics of the study population
| yHC | eHC | MCI PIB-positive (Prodromal AD) | AD dementia | PSP | CBD | MCI PIB-negative | |
|---|---|---|---|---|---|---|---|
| n | 5 | 4 | 11 | 9 | 1 | 1 | 2 |
| Age, years | 22 [22:28] | 62 [60.3:65] | 73 [65:74] | 67 [60:74] | 66 | 69 | 64 ; 79 |
| Gender (male/female) | 0/5 | 3/1 | 5/6 | 2/7 | 1/0 | 1/0 | 1/1 |
| ApoE ε4 frequency | n/a | n/a | 6 (60 %)† | 7 (78 %) | 0 (0 %) | n/a | 0 (0 %)† |
| Education, years | 15 [14.3:17] | 14 [12.5:15.5] | 12 [10:14] | 14 [12:15] | 9 | 15 | 8 ; 18 |
| MMSE | n/a | n/a | 29 [27.5:29.5] a | 24 [23:25] | 24 | 23 | 23 ; 27 |
| Global cognition, z-scores | 0.9 [0.9:1.2] | −0.6 [−1.1:0.0] | −0.5 [−0.8:0.2] | −2.5 [−6.3:0.3] b | −3.3 | −3.3 | −1.0 ; −1.5 |
| Episodic memory, z-scores | 1.0 [0.7:1.2] | −0.7 [−1.2:0.7] | −1.5 [−1.9:0.1] a | −2.6 [−2.8:-2.0] b | n/a | −2.0 | −1.0 ; −0.9 |
| Time PIB to THK5317, days |
n/a | 0 [0–2] | 0 [0–4] | 0 [0–7] | 0 | 9 | 0 ; 0 |
| Time FDG to THK5317, days |
n/a | n/a | 56 [38:84] | 60 [41:64] | 106 | 92 | 101 ; 620 |
| Time CSF to THK5317, days |
n/a | n/a | 745 [492:993] | 857 [391:1888] | 103 | 694 | 558 ; 636 |
| CSF Aβ1–42, pg/mL | n/a | n/a | 547 [506.3:851]§ | 484.5 [449.8:526.5]† | 693 | 1700 | 607 ; 792 |
| CSF t-tau, pg/mL | n/a | n/a | 465 [301:492]‡ | 546 [368:675.8]† | 239 | 644 | 210 ; 933 |
| CSF p-tau181p, pg/mL | n/a | n/a | 62.5 [49.8:86.5]§ | 82 [57:104.3]† | 36 | 98 | 36 ; 120 |
Significant differences with a Bonferroni-corrected threshold of p < 0.016 for pair-wise comparisons arelative to patients with AD dementia; brelative to all HC (i.e. yHC and eHC)
Data are presented as medians [Interquartile range], or as n(%). Aβ amyloid-beta, AD Alzheimer’s disease, ApoE apolipoprotein E, CBD corticobasal degeneration, eHC elderly healthy controls, FDG [18F]FDG, MMSE mini mental state examination, n/a results not available, PIB [11C]Pittsburgh compound B, MCI PIB-positive/negative mild cognitive impairment with [11C]PIB uptake above/below the normal range (threshold standard uptake value ratio of 1.41), PSP progressive supranuclear palsy, THK5317 [18F]THK5317, yHC young healthy controls
†data missing for one individual
‡data missing for three individuals
§data missing for four individuals